In the rivaroxaban 10‐mg stratum, there was a nominally significant lower incidence of symptomatic VTE in the age ≥75 group with rivaroxaban compared with placebo: 0.1% and 0.7% respectively, HR 0.11, 95% CI 0.01‐0.86; the interaction p ‐value for age group was .20.
← all excerpts
Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older.
1
—
—